Shire €53bn buyout cleared

Takeda Pharmaceutical has cleared a hurdle for its $62bn (€53bn) acquisition of Shire, receiving unconditional approval from the US Federal Trade Commission two months after sealing its biggest deal ever.

The purchase remains subject to a number of conditions, the Japanese company said in a statement, including other regulatory clearances and approval by shareholders of both companies.